Medico-economic Interest of the Protein S100b in Mild Head Trauma Under Anti-thrombotics (ISTCAT)

Rennes University Hospital

Status: Completed

Conditions: Mild Head Injury; Antiplatelet; Anticoagulant

Treatments: Other: Dosage of S100β protein

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT04305821

35RC19_30046_ISTCAT

Details and patient eligibility

About

Head trauma is a common injury in emergency department. Investigation to search for complication is guided by the clinical examination and the case history, such as taking anti-thrombotics. Cranial computed tomography (CCT) is the gold standard to investigate, and is mandatory in case of antithrombotic drugs.

Recently, some biomarkers have proven their utility to rule-out mild head trauma without CCT in the general population. Among these biomarkers, S100β protein has been added in guidelines for mild head trauma. Some studies have found similar data in population taking anticoagulant or antiplatelet drugs.

The investigators aim to prove medical utility of S100β protein in population under antithrombotics, by the reduction of CCT use. Then, The investigators hypothesize that the add of S100β protein reduces cost of health care in the management of head injury in that population.

Enrollment: 260 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient ≥ 18 years old
• Taking antithrombotic medication (antiplatelet drugs, K vitamin antagonist, direct oral anticoagulants, heparins)
• Mild head trauma with Glasgow coma scale ≥ 13
• Trauma occured ≤ 6 hours
• Agreeing the participation in the study

Exclusion criteria

• Head injury occured > 6 hours
• Patient < 18 years old or under juridic protection
• pregnant women
• polytrauma
• Glasgow coma scale ≤ 12
• ancient or actual cerebral ou cutaneous neoplasia